New insider activity at BioCardia ( (BCDA) ) has taken place on September 23, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a significant show of confidence in BioCardia, key executives have made substantial stock purchases. President & CEO Peter Altman acquired 48,000 shares valued at $60,000. Director Simon H. Stertzer made an even larger investment, purchasing 398,400 shares for $498,000. Meanwhile, Director Andrew Scott Blank bought 288,000 shares, amounting to $360,000. These transactions highlight a strong belief in the company’s potential by its leadership.
Recent Updates on BCDA stock
In recent developments, BioCardia announced a positive preliminary clinical consultation with Japan’s PMDA regarding the CardiAMP Heart Failure Trial results, which could potentially enhance its market position by addressing significant therapeutic needs. However, the PMDA requested additional information on various trial aspects, which BioCardia plans to address before a formal consultation later this year. Financially, BioCardia completed a significant transaction by selling 4.8 million shares, raising approximately $5.1 million, expected to bolster its financial position. Despite these developments, BioCardia’s stock is rated as Neutral due to weak financial performance, bearish technical indicators, and negative valuation metrics, overshadowing positive clinical trial progress.
Spark’s Take on BCDA Stock
According to Spark, TipRanks’ AI Analyst, BCDA is a Neutral.
BioCardia’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. The negative valuation metrics further weigh down the score. While the earnings call highlighted some positive developments in clinical trials and regulatory progress, the financial challenges and market sentiment remain significant concerns.
To see Spark’s full report on BCDA stock, click here.
More about BioCardia
YTD Price Performance: -50.88%
Average Trading Volume: 665,719
Technical Sentiment Signal: Sell
Current Market Cap: $6.45M